A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT ID: NCT01589510

Last Updated: 2014-06-13

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 419 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2013-02-28

Brief Summary

A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

Conditions

Glaucoma, Open-Angle; Ocular Hypertension

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Lumigan® 0.01%

Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.

bimatoprost 0.01% ophthalmic solution

Intervention Type: DRUG

Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.

Interventions

bimatoprost 0.01% ophthalmic solution

Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.

Intervention Type: DRUG

Other Intervention Names

Lumigan® 0.01%

Eligibility Criteria

Inclusion Criteria

• Diagnosis of POAG or OHT
• Prescribed Lumigan® 0.01%

Exclusion Criteria

• None

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allergan

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Allergan

Locations

Vienna, , Austria

Countries

Austria

Other Identifiers

MAF/AGN/OPH/GLA/034

Identifier Type: -

Identifier Source: org_study_id